PO.PS01.06 · 人群科学
农村与城市地区随时间变化的烟草使用、戒烟干预和肺癌筛查模式:一项为期10年的回顾性队列研究
Patterns of tobacco use, cessation interventions, and lung cancer screening in rural vs. urban areas over time; a 10-year retrospective cohort study
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:肺癌发病率在农村和城市地区之间存在差异,但很少有研究评估整个风险-筛查连续体上的城乡差异。我们在一个地理定义的区域内考察了10年间城乡连续体上的吸烟、戒烟干预和肺癌筛查模式。
材料与方法:采用来自罗切斯特流行病学项目的临床数据开展了一项回顾性队列研究(2014-2023年),该数据源自美国中西部一个27个县区域的医疗就诊记录。纳入年龄40-80岁的患者。我们使用城乡通勤区代码将居住地划分为城市、农村或高度农村。我们考察了年度吸烟患病率、戒烟干预(药物治疗、咨询)和低剂量计算机断层扫描(LDCT)肺癌筛查。
结果:在10年研究期间,样本量每年在305,530至340,411人之间,其中36-38%为城市,56-57%为农村,6-7%为高度农村。当前吸烟患病率在10年期间从14%下降至12%(范围=12-16%;p=0.06),且城市地区(范围=10-14%)持续低于农村(范围=12-17.0%)和高度农村地区(范围=12-18%;p<0.001)。在当前吸烟且无肺癌史的个体中,年度戒烟干预率在16%至23%之间,10年期间呈上升趋势(p<0.001)。戒烟药物(伐尼克兰、安非他酮或尼古丁替代品)处方总体上随时间持续增加,但城市地区仍高于农村和高度农村地区(p<0.001)。戒烟咨询率也随时间总体增加,城市和农村地区相似,而高度农村地区较低(p<0.001)。在年龄50-80岁、曾吸烟且无肺癌诊断的人群中,LDCT筛查率在研究期间从0.0%增加至3.1%。城市地区增幅较高(0.0-3.6%),农村和高度农村地区相似(分别为0.0-2.8%和0.0-2.9%;p<0.001)。在当前吸烟人群中,LDCT筛查率在研究期间也有所增加(0.0-6.4%),城市地区(0.1-8.0%)增幅高于农村(0.0-5.7%)或高度农村(0.1-6.1%)地区(p<0.001)。在2021年新筛查指南发布后,所有地区的筛查率逐年上升。
结论:在该队列中,我们发现2014-2023年间城乡连续体上的吸烟患病率、戒烟干预和肺癌筛查均有所改善。遗憾的是,与城市相比,农村地区的吸烟患病率仍较高,戒烟干预和筛查率仍较低。这些持续存在的模式凸显了需要制定策略以克服农村居民的障碍,并在所有地区改善肺癌预防和早期检测。
查看英文原文 English abstract
Introduction: Lung cancer rates differ across rural and urban areas, but few studies have evaluated rural-urban differences across the risk-screening continuum. We examined smoking, cessation interventions, and lung cancer screening patterns across the rural-urban continuum in a geographically defined area over 10 years.
Materials and Methods: A retrospective cohort study (2014-2023) was conducted using clinical data from the Rochester Epidemiology Project, derived from healthcare encounters in a 27-county region of the midwestern United States. Patients ages 40-80 were included. We used Rural-Urban Commuting Area codes to assign residence as urban, rural, or highly rural. We examined yearly smoking prevalence, cessation intervention (pharmacotherapy, counseling), and low-dose computed tomography (LDCT) lung cancer screening.
Results: Over the 10-year study period, the sample size ranged from 305,530 to 340,411 people annually with 36-38% urban, 56-57% rural, and 6-7% highly rural. Current smoking prevalence declined from 14 to 12% over the 10-year period (range=12-16%; p =0.06) and was consistently lower in urban areas (range=10-14%) than rural (range=12-17.0%) and highly rural areas (range=12-18%; p =<0.001). Among individuals who currently smoked with no history of lung cancer, yearly smoking cessation intervention ranged from 16% to 23%, increasing over the 10-year period ( p =<0.001). Cessation medication (varenicline, bupropion, or nicotine replacement) prescription consistently increased overall over time but remained higher in urban than rural and highly rural areas ( p =<0.001). Cessation counseling rates also increased overall over time and were similar between urban and rural areas and lower in highly rural areas ( p =<0.001). Among people who had ever-smoked aged 50-80 years with no diagnosis of lung cancer, LDCT screening increased from 0.0% to 3.1% over the study period. Increases were higher in urban areas (0.0-3.6%) and similar in rural and highly rural areas (0.0-2.8% and 0.0-2.9%, respectively; p =<0.001). Among people who currently smoked, LDCT screening also increased over the study period (0.0-6.4%), with higher increases in urban (0.1-8.0%) than rural (0.0-5.7%) or highly rural (0.1-6.1%) areas ( p =<0.001). After the new screening guidelines in 2021, rates in all areas increased year-on-year.
Conclusion: In this cohort, we found that smoking prevalence, cessation interventions, and lung cancer screening improved from 2014-2023 across the rural-urban continuum. Unfortunately, smoking prevalence remained higher and cessation interventions and screening rates lower in rural compared to urban areas. The persistent patterns underscore the need for strategies to overcome barriers for rural residents and improve lung cancer prevention and early detection in all areas.
利益披露 Disclosure
B. Tranby, None..
P. A. Decker, None..
J. Ruoxiang, None..
D. Midthun, None.
L. C. Sakoda,
AstraZeneca ).
M. C. Aldrich, None..
D. Friedman, None..
A. Manful, None..
O. Bhattacharyya, None..
C. Patten, None..
C. A. Doubeni, None.